ULURU Inc. Announces Status of York Note ...( ADDISON Texas July ...),Health

ADDISON, Texas, July 27 /PRNewswire-FirstCall/ -- ULURU Inc. (NYSE Amex: ULU) ("the Company") today announced that it has collected $1,024,544 which represents all of the accrued and unpaid principal and interest associated with the Promissory Note ("Note Agreement") between the Company and York Pharma, plc ("York").

In order to consummate the remittance, on July 22, 2009, the Company entered into a Forbearance Agreement where the Company agreed, in exchange for a payment of $250,000, to forbear for a period of no more than seven days from exercising its rights and remedies under the Note Agreement and certain related loan documents.

The payment received from York was applied first to unpaid interest and then the remainder to reduce the aggregate principal amount owed to the Company. Accordingly, the aggregate principal amount payable to the Company was reduced to $774,246. The Forbearance Agreement provided that the remaining principal would accrue interest at an increased rate of 14% per annum.

On July 24, 2009, the Company assigned all of its interest in and to its rights, benefits and obligations under the Note Agreement to an unrelated third party in exchange for a cash payment of $774,246 plus all accrued but unpaid interest. As a result of such assignment, the Company no longer has any interest in the Loan Documents.

Renaat Van den Hooff, President & CEO of ULURU Inc., commented: "We are very pleased that we've been able to recuperate the amounts owed to our Company. It certainly gives us more breathing room and allows us to focus on the available options for strategic partnerships and continuation of our business plan."

About ULURU Inc.:

ULURU Inc. is a specialty pharmaceutical company focused on the deve
'/>"/>